{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:49:38Z","timestamp":1771879778479,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.clinthera.2009.08.010","type":"journal-article","created":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T04:47:47Z","timestamp":1254804467000},"page":"1652-1663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers"],"prefix":"10.1016","volume":"31","author":[{"given":"Kelly","family":"Makarounas-Kirchmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Glover-Koudounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.08.010_bib1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [published correction appears in N Engl J Med. 1994;330:1689]","volume":"328","author":"Materson","year":"1993","journal-title":"N EnglJ Med."},{"key":"10.1016\/j.clinthera.2009.08.010_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjmed.2003.08.027","article-title":"Calcium channel blockers: An update","volume":"116","author":"Eisenberg","year":"2004","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2009.08.010_bib3","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM198212233072605","article-title":"Mechanism of action of calcium-channel-blocking agents","volume":"307","author":"Braunwald","year":"1982","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.08.010_bib4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0895-7061(02)03000-5","article-title":"Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives","volume":"15","author":"Leonetti","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2009.08.010_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0002-9149(00)01199-1","article-title":"Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension","volume":"86","author":"Messerli","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2009.08.010_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4943(03)00047-5","article-title":"Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: The ELderly and LErcanidipine (ELLE) study","volume":"37","author":"Cherubini","year":"2003","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.clinthera.2009.08.010_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.jhh.1001614","article-title":"Lercanidipine vs lacidipine in isolated systolic hypertension","volume":"17","author":"Millar-Craig","year":"2003","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2009.08.010_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archinte.159.7.693","article-title":"Physical Symptoms Distress Index: A sensitive tool to evaluate the impact of pharmacological agents on quality of life","volume":"159","author":"Anderson","year":"1999","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2009.08.010_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5694\/j.1326-5377.2008.tb01589.x","article-title":"Persistence with antihy-pertensive medication: Australia-wide experience, 20042006","volume":"188","author":"Simons","year":"2008","journal-title":"Med J Aust"},{"key":"10.1016\/j.clinthera.2009.08.010_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/08038020310000087","article-title":"Improved tolerability of the dihydropyri-dine calcium-channel antagonist lercanidipine: The ler-canidipine challenge trial","volume":"1","author":"Borghi","year":"2003","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.clinthera.2009.08.010_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1211\/0022357991772844","article-title":"Vascular-selective effect of lercanidipine and other 1,4-dihydropyri-dines in isolated rabbit tissues","volume":"51","author":"Angelico","year":"1999","journal-title":"J Pharm Pharmacol."},{"key":"10.1016\/j.clinthera.2009.08.010_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00132580-200111000-00008","article-title":"Lercanidipine: A novel dihydropyridine calcium-channel blocker","volume":"3","author":"Epstein","year":"2001","journal-title":"Heart Dis."},{"key":"10.1016\/j.clinthera.2009.08.010_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/080370598438998","article-title":"Ler-canidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties","volume":"2","author":"Herbette","year":"1998","journal-title":"Blood Press Suppl."},{"key":"10.1016\/j.clinthera.2009.08.010_bib14","first-page":"173","article-title":"Lercanidipine in hypertension","volume":"1","author":"Borghi","year":"2005","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.clinthera.2009.08.010_bib15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1345\/aph.1H299","article-title":"Lercanidipine in the treatment of hypertension","volume":"41","author":"Beckey","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.08.010_bib16","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/00005344-199729002-00006","article-title":"Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: A comparative study with slow-release nifedipine","volume":"29","author":"Policicchio","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2009.08.010_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1524-6175.2003.01960.x","article-title":"Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study","volume":"5","author":"Romito","year":"2003","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2009.08.010_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.309.6954.597","article-title":"Rationale for systematic reviews","volume":"309","author":"Mulrow","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2009.08.010_bib19","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2008"},{"key":"10.1016\/j.clinthera.2009.08.010_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: An update","volume":"8","author":"Der Simonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clinthera.2009.08.010_bib21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0011-393X(00)90012-2","article-title":"Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: A double-blind, randomized, parallel-group study","volume":"61","author":"Fogari","year":"2000","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.clinthera.2009.08.010_bib22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/00004872-200305000-00026","article-title":"Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine","volume":"21","author":"Lund-Johansen","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2009.08.010_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02850100","article-title":"Therapeutic profile of manidipine and lercanidipine in hypertensive patients","volume":"21","author":"Casiglia","year":"2004","journal-title":"Adv Ther."},{"key":"10.1016\/j.clinthera.2009.08.010_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5694\/j.1326-5377.2003.tb05471.x","article-title":"Untreated hypertension among Australian adults: The 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab)","volume":"179","author":"Briganti","year":"2003","journal-title":"Med J Aust."},{"key":"10.1016\/j.clinthera.2009.08.010_bib25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension."},{"key":"10.1016\/j.clinthera.2009.08.010_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.311.7000.293","article-title":"Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ."},{"key":"10.1016\/j.clinthera.2009.08.010_bib27","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/01.hjh.0000187261.40190.2e","article-title":"Rate and determinants of 10-year persistence with antihypertensive drugs","volume":"23","author":"Van Wijk","year":"2005","journal-title":"J Hypertens."},{"key":"10.1016\/j.clinthera.2009.08.010_bib28","first-page":"11","article-title":"Use and adverse reactions of antihypertensive drugs in Spain Part I of the RAAE Study","volume":"1","author":"Aranda","year":"1997","journal-title":"Blood Press Suppl."},{"key":"10.1016\/j.clinthera.2009.08.010_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/080370598437187","article-title":"Changes in antihypertensive therapy\u2014the role of adverse effects and compliance","volume":"7","author":"D\u00fcsing","year":"1998","journal-title":"Blood Press."},{"key":"10.1016\/j.clinthera.2009.08.010_bib30","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/VHRM.S3510","article-title":"Patient adherence and the choice of antihypertensive drugs: Focus on lercanidipine","volume":"4","author":"Pruijm","year":"2008","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.clinthera.2009.08.010_bib31","first-page":"999","article-title":"A prospective evaluation of persistence on antihypertensive treatment with different antihyper-tensive drugs in clinical practice","volume":"3","author":"Veronesi","year":"2007","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.clinthera.2009.08.010_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-8703(99)70312-1","article-title":"Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials","volume":"138","author":"He","year":"1999","journal-title":"Am Heart J."},{"key":"10.1016\/j.clinthera.2009.08.010_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7410","article-title":"The inclusion of reports of randomised trials published in languages other than English in systematic reviews","volume":"7","author":"Moher","year":"2003","journal-title":"Health Technol Assess."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809002938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809002938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:07Z","timestamp":1758962887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0149291809002938"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.08.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}